Search results for "Disc"

showing 10 items of 19256 documents

On multivalued weakly Picard operators in partial Hausdorff metric spaces

2015

We discuss multivalued weakly Picard operators on partial Hausdorff metric spaces. First, we obtain Kikkawa-Suzuki type fixed point theorems for a new type of generalized contractive conditions. Then, we prove data dependence of a fixed points set theorem. Finally, we present sufficient conditions for well-posedness of a fixed point problem. Our results generalize, complement and extend classical theorems in metric and partial metric spaces.

multivalued operatorDiscrete mathematicsApplied MathematicsInjective metric spacedata dependencepartial metric spaceFixed-point theoremEquivalence of metricsConvex metric spaceIntrinsic metricMetric spaceHausdorff distancefixed pointSettore MAT/05 - Analisi MatematicaMetric (mathematics)Geometry and TopologyMathematicsFixed Point Theory and Applications
researchProduct

Search for Electron Antineutrino Appearance in a Long-baseline Muon Antineutrino Beam

2020

Electron antineutrino appearance is measured by the T2K experiment in an accelerator-produced antineutrino beam, using additional neutrino beam operation to constrain parameters of the Pontecorvo-Maki-Nakagawa-Sakata (PMNS) mixing matrix. T2K observes 15 candidate electron antineutrino events with a background expectation of 9.3 events. Including information from the kinematic distribution of observed events, the hypothesis of no electron antineutrino appearance is disfavored with a significance of 2.40 σ and no discrepancy between data and PMNS predictions is found. A complementary analysis that introduces an additional free parameter which allows non-PMNS values of electron neutrino and a…

muon antineutrino beamGeneral Physics and Astronomyantineutrino/mu: secondary beamKAMIOKANDEantineutrino/e: particle identification01 natural sciences09 EngineeringHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)secondary beam [neutrino/mu][PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]neutrino/e: particle identificationQCPhysics02 Physical SciencesPhysicsJ-PARC LabT2K experimentelectron antineutrinoT2K CollaborationkinematicsPhysical SciencesParticle Physics - ExperimentT2K experiment in an accelerator-producedGeneral Physics530 PhysicsPhysics MultidisciplinaryFOS: Physical sciencesparticle identification [antineutrino/e]Neutrino beamsecondary beam [antineutrino/mu]530Physics::GeophysicsNuclear physics0103 physical sciencesmixingddc:530010306 general physics01 Mathematical SciencesMuonScience & Technologyparticle identification [neutrino/e]hep-exbackgroundHigh Energy Physics - Experiment; High Energy Physics - Experimentneutrino/mu: secondary beamantineutrino: oscillationoscillation [antineutrino]Elementary Particles and FieldsHigh Energy Physics::ExperimentPMNSElectron neutrinoBeam (structure)Free parameterexperimental results
researchProduct

Cardiolipin content controls mitochondrial coupling and energetic efficiency in muscle

2020

Decreasing mitochondrial energy-production efficiency in skeletal muscle can confer protection against diet-induced obesity.

muscle[SDV]Life Sciences [q-bio]Respiratory chainDiseases and DisordersOxidative phosphorylation[SDV.BC]Life Sciences [q-bio]/Cellular Biology030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineCardiolipin[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular Biology[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyInner mitochondrial membrane[SDV.BC] Life Sciences [q-bio]/Cellular BiologyResearch ArticlesFatty acid synthesisComputingMilieux_MISCELLANEOUS030304 developmental biology2. Zero hungerchemistry.chemical_classification0303 health sciencesMultidisciplinary[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyATP synthasebiologyfungifood and beveragesSciAdv r-articlesSkeletal muscleFatty acidCell BiologymitochondrialCell biologymedicine.anatomical_structurechemistryCardiolipinbiology.protein[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyResearch Article
researchProduct

2016

Background Contractile myofibroblasts (MFs) accumulate in the joint capsules of patients suffering from posttraumatic joint stiffness. MF activation is controlled by a complex local network of growth factors and cytokines, ending in the increased production of extracellular matrix components followed by soft tissue contracture. Despite the tremendous growth of knowledge in this field, inconsistencies remain in practice and prevention.

musculoskeletal diseases0301 basic medicinePathologymedicine.medical_specialtyPlatelet-derived growth factormacromolecular substancesBiologyExtracellular matrix03 medical and health scienceschemistry.chemical_compound0302 clinical medicineJoint capsulemedicine030222 orthopedicsMultidisciplinaryCell biology030104 developmental biologymedicine.anatomical_structurechemistrybiology.proteinContracturemedicine.symptomSignal transductionMyofibroblastPlatelet-derived growth factor receptorTransforming growth factorPLOS ONE
researchProduct

RNA-mediated therapies in myotonic dystrophy

2018

Myotonic dystrophy 1 (DM1) is a multisystemic neuromuscular disease caused by a dominantly inherited 'CTG' repeat expansion in the gene encoding DM Protein Kinase (DMPK). The repeats are transcribed into mRNA, which forms hairpins and binds with high affinity to the Muscleblind-like (MBNL) family of proteins, sequestering them from their normal function. The loss of function of MBNL proteins causes numerous downstream effects, primarily the appearance of nuclear foci, mis-splicing, and ultimately myotonia and other clinical symptoms. Antisense and other RNA-mediated technologies have been applied to target toxic-repeat mRNA transcripts to restore MBNL protein function in DM1 models, such as…

musculoskeletal diseases0301 basic medicinePharmacologycongenital hereditary and neonatal diseases and abnormalitiesMessenger RNAMyotonin-protein kinaseRNABiologymedicine.diseaseMyotoniaMyotonic dystrophyMyotonin-Protein KinaseCell biology03 medical and health sciences030104 developmental biologyDrug DiscoverymedicineAnimalsHumansMyotonic DystrophyRNARNA MessengerTrinucleotide repeat expansionGeneLoss functionDrug Discovery Today
researchProduct

<p>Effects of losartan and atorvastatin on the development of early posttraumatic joint stiffness in a rat model</p>

2019

Background After a trauma, exuberant tissue healing with fibrosis of the joint capsule can lead to posttraumatic joint stiffness (PTJS). Losartan and atorvastatin have both shown their antifibrotic effects in different organ systems. Objective The purpose of this study was the evaluation of the influence of losartan and atorvastatin on the early development of joint contracture. In addition to joint angles, the change in myofibroblast numbers and the distribution of bone sialoprotein (BSP) were assessed. Study design and methods In this randomized and blinded experimental study with 24 rats, losartan and atorvastatin were compared to a placebo. After an initial joint injury, rat knees were …

musculoskeletal diseases0301 basic medicinePharmacologymedicine.medical_specialtyArticular capsule of the knee jointbusiness.industryAtorvastatinUrologyPharmaceutical SciencePlacebo03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureLosartan030220 oncology & carcinogenesisJoint stiffnessDrug DiscoveryJoint capsulemedicineJoint Contracturemedicine.symptomContracturebusinessmedicine.drugDrug Design, Development and Therapy
researchProduct

Myotonic dystrophy: candidate small molecule therapeutics

2017

Myotonic dystrophy type 1 (DM1) is a rare multisystemic neuromuscular disorder caused by expansion of CTG trinucleotide repeats in the noncoding region of the DMPK gene. Mutant DMPK transcripts are toxic and alter gene expression at several levels. Chiefly, the secondary structure formed by CUGs has a strong propensity to capture and retain proteins, like those of the muscleblind-like (MBNL) family. Sequestered MBNL proteins cannot then fulfill their normal functions. Many therapeutic approaches have been explored to reverse these pathological consequences. Here, we review the myriad of small molecules that have been proposed for DM1, including examples obtained from computational rational …

musculoskeletal diseases0301 basic medicineTherapeutic gene modulationcongenital hereditary and neonatal diseases and abnormalitiesMutantComputational biologyBiologyMyotonic dystrophyMyotonin-Protein Kinase03 medical and health sciences0302 clinical medicineTrinucleotide RepeatsDrug DiscoveryGene expressionmedicineAnimalsHumansMyotonic DystrophyGenePharmacologyRegulation of gene expressionGeneticsDrug RepositioningRational designmedicine.diseaseSmall moleculeHigh-Throughput Screening Assays030104 developmental biologyGene Expression RegulationDrug Design030217 neurology & neurosurgeryDrug Discovery Today
researchProduct

Derepressing muscleblind expression by miRNA sponges ameliorates myotonic dystrophy-like phenotypes in Drosophila

2016

AbstractMyotonic Dystrophy type 1 (DM1) originates from alleles of the DMPK gene with hundreds of extra CTG repeats in the 3′ untranslated region (3′ UTR). CUG repeat RNAs accumulate in foci that sequester Muscleblind-like (MBNL) proteins away from their functional target transcripts. Endogenous upregulation of MBNL proteins is, thus, a potential therapeutic approach to DM1. Here we identify two miRNAs, dme-miR-277 and dme-miR-304, that differentially regulate muscleblind RNA isoforms in miRNA sensor constructs. We also show that their sequestration by sponge constructs derepresses endogenous muscleblind not only in a wild type background but also in a DM1 Drosophila model expressing non-co…

musculoskeletal diseases0301 basic medicineUntranslated regioncongenital hereditary and neonatal diseases and abnormalitiesMotor ActivityBiologyMyotonic dystrophyArticle03 medical and health sciences0302 clinical medicineRNA IsoformsmicroRNAmedicineAnimalsDrosophila ProteinsMyotonic DystrophyRegulation of gene expressionGeneticsMultidisciplinaryWild typeNuclear Proteinsmedicine.diseaseMicroRNAsDrosophila melanogasterPhenotype030104 developmental biologyGene Expression RegulationFlight AnimalTrinucleotide Repeat ExpansionTrinucleotide repeat expansion030217 neurology & neurosurgeryDrosophila ProteinScientific Reports
researchProduct

Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis ge…

2016

AbstractMyotonic dystrophies (DM1–2) are neuromuscular genetic disorders caused by the pathological expansion of untranslated microsatellites. DM1 and DM2, are caused by expanded CTG repeats in the 3′UTR of the DMPK gene and CCTG repeats in the first intron of the CNBP gene, respectively. Mutant RNAs containing expanded repeats are retained in the cell nucleus, where they sequester nuclear factors and cause alterations in RNA metabolism. However, for unknown reasons, DM1 is more severe than DM2. To study the differences and similarities in the pathogenesis of DM1 and DM2, we generated model flies by expressing pure expanded CUG ([250]×) or CCUG ([1100]×) repeats, respectively, and compared …

musculoskeletal diseases0301 basic medicinecongenital hereditary and neonatal diseases and abnormalitiesRNA SplicingScienceGene ExpressionBiologyMyotonic dystrophyMyotonin-Protein KinaseArticle03 medical and health sciencesGene expressionAutophagymedicineAnimalsMyotonic DystrophyMuscle SkeletalGeneDNA Repeat ExpansionMultidisciplinaryMyocardiumQRIntronRNAArrhythmias CardiacDNA Repeat Expansionmedicine.diseaseMolecular biologyDisease Models AnimalCell nucleus030104 developmental biologymedicine.anatomical_structureRNA splicingMedicineDrosophilaLocomotionScientific Reports
researchProduct

miR-7 Restores Phenotypes in Myotonic Dystrophy Muscle Cells by Repressing Hyperactivated Autophagy

2019

International audience; Unstable CTG expansions in the 3' UTR of the DMPK gene are responsible for myotonic dystrophy type 1 (DM1) condition. Muscle dysfunction is one of the main contributors to DM1 mortality and morbidity. Pathways by which mutant DMPK trigger muscle defects, however, are not fully understood. We previously reported that miR-7 was downregulated in a DM1 Drosophila model and in biopsies from patients. Here, using DM1 and normal muscle cells, we investigated whether miR-7 contributes to the muscle phenotype by studying the consequences of replenishing or blocking miR-7, respectively. Restoration of miR-7 with agomiR-7 was sufficient to rescue DM1 myoblast fusion defects and…

musculoskeletal diseases0301 basic medicineoligonucleotidemuscle atrophyautophagyBiologyMyotonic dystrophyArticleMuscleblind03 medical and health scienceschemistry.chemical_compoundMyoblast fusion0302 clinical medicineDrug DiscoverymicroRNAmedicineMBNL1MyocyteMyotonic DystrophymiRNAtherapy[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyAutophagyUPS systemmiR-7medicine.diseasePhenotypeMuscle atrophyCell biology030104 developmental biologychemistry030220 oncology & carcinogenesisMolecular MedicineCTG expansionsmedicine.symptom[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct